Genetically modified immunocompetent cells in HIV infection

Gene Therapy

Volumn 8, Issue 21, 2001, Pages 1593-1600

  Palu G ^a   Pira, G Li ^b   Gennari, F ^a   Fenoglio, D ^b   Parolin, C ^a   Manca, F ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b Advanced Biotechnology Center   (Italy)

Author keywords

Cell therapy; Gene therapy; HIV; Immunoreconstitution; Opportunistic pathogens; T cell repertoire

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; DNA; GANCICLOVIR; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; HYGROMYCIN; INTERLEUKIN 2; NERVE GROWTH FACTOR RECEPTOR; REV PROTEIN; THYMIDINE KINASE; TRANSFER RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOPTIVE IMMUNOTHERAPY; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; CONTROLLED STUDY; DNA MODIFICATION; GENE TARGETING; GENE THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPETENT CELL; INFECTION CONTROL; LEUKAPHERESIS; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

ADOPTIVE TRANSFER; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD34; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COMBINED MODALITY THERAPY; CRYOPRESERVATION; EPITOPES; GENE THERAPY; GENES, TAT; HIV; HIV INFECTIONS; HUMANS; TISSUE PRESERVATION;

HUMAN IMMUNODEFICIENCY VIRUS; RNA VIRUSES;

EID: 0035186203     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301569     Document Type: Review

References (103)

1. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
2. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
3. + T-cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
4. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy
5. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy
6. Toward HIV eradication or remission: The tasks ahead
7. + T lymphocytes
8. + cell noncytotoxic anti-HIV activity in individuals receiving highly active antiretroviral therapy during primary infection
9. Management of the adverse effects of antiretroviral therapy and medication adherence
10. Viral genetic heterogeneity in HIV-1-infected individuals is associated with increasing use of HAART and higher viraemia
11. Antiretroviral resistance during successful therapy of HIV type 1 infection
12. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA Panel
13. Antiretroviral drug resistance testing in adult HIV-1 infection: Recommendations of an International AIDS Society-USA Panel
14. Genetic strategies to inhibit HIV
15. Gene therapy for the treatment of AIDS: Animal models and human clinical experience
16. Progress with retroviral gene vectors
17. In vitro T lymphopoiesis: A model system for stem cell gene therapy for AIDS
18. Protection of primary human T cells from HIV infection by Trev: A transdominant fusion gene
19. + T cell proliferation in HIV-positive patients as a result of CD28 costimulation
20. Molecular components of T-cell recognition
21. HIV envelope glycoprotein, antigen specific T-cell response and soluble CD4
22. T-lymphocyte recognition of antigen in association with gene products of the major histocompatibility complex
23. + hematopoietic progenitor cells with an antitat gene protects T-cell and macrophage progeny from AIDS virus infection
24. Transduction of human macrophages using a stable HIV-1/HIV-2-derived gene delivery system
25. Intrinsic human immunodeficiency virus type 1 resistance of hematopoietic stem cells despite coreceptor expression
26. Suitability of bone marrow from HIV-1-infected donors for retrovirus-mediated gene transfer
27. Mobilization of peripheral blood progenitor cells for human immunodeficiency virus-infected individuals
28. + hematopoietic cells with a hairpin ribozyme protects T cells and macrophages from simian immunodeficiency virus infection
29. RevM10-expressing T cells derived in vivo from transduced human hematopoietic stem-progenitor cells inhibit human immunodeficiency virus replication
30. T cell antigen receptor genes and T-cell recognition
31. + cells in vitro
32. Mending a broken HAART
33. Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomised controlled trial
34. Introduction of HIV-drug resistance testing in clinical practice
35. Ribozymes as potential anti-HIV-1 therapeutic agents
36. Peripheral blood lymphocytes as target cells of retroviral vector-mediated gene transfer
37. + cells transduced with retroviral vectors containing an intracytoplasmatically truncated version of the human low-affinity nerve growth factor receptor (deltaLNGFR) gene
38. Enhanced T cell engraftment after retroviral delivery of an antiviral gene in HIV-infected individuals
39. A controlled, phase 1 clinical trial to evaluate the safety and effects in HIV-1 infected humans of autologous lymphocytes transduced with a ribozyme that cleaves HIV-1 RNA
40. + lymphoid cells
41. MLV-derived retroviral vectors selective for CD4-expressing cells and resistant to neutralization by sera from HIV-infected patients
42. AIDS: A disease of impaired Th-cell renewal?
43. HIV infection: Where have all the T cells gone?
44. HIV-1 entry into quiescent primary lymphocytes: Molecular analysis reveals a labile, latent viral structure
45. Activation of virus replication after vaccination of HIV-1-infected individuals
46. Down-modulation of TCR/CD3 surface complex after HIV-1 infection is associated with differential expression of the viral regulatory genes
47. T-cell-mediated immunopathology versus direct cytolysis by virus: Implications for HIV and AIDS
48. Generation of HIV latency during thymopoiesis
49. Clinical spectrum of human immunodeficiency virus diseases
50. Immunity to intracellular bacteria
51. + T helper type 1 cell responses to Candida albicans
52. Adoptive transfer of lymphocytes sensitized to the major surface glycoprotein of Pneumocystis carinii confers protection in the rat
53. + T cell response depending on the route of immunization
54. + cytotoxic T-cell responses during chronic viral infection
55. + T cell responses associated with control of viremia
56. Immune responses to human immunodeficiency virus infection
57. Virus-specific CD8 cytotoxic T lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection
58. Cytotoxic T-cell responses, viral load, and disease progression in early human immundeficiency virus type 1 infection
59. Principles for adoptive T cell therapy of human viral diseases
60. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes
61. In vivo migration and function of transferred HIV-1-specific cytotoxic T cells
62. + T-cell repertoire that are not immediately restored by antiviral or immune-based therapies
63. Persistent alterations in T-cell repertoire, cytokine and chemokine receptor gene expression after 1 year of highly active antiretroviral therapy
64. Perturbation of CD4 and CD8 T cell repertoires during progression to AIDS and regulation of CD4 repertoire during antiretroviral therapy
65. + T-cell regeneration in HIV-infected adults
66. + T lymphocyte lines from HIV-1 seropositive patients
67. Recognition of antigenic clusters of Candida albicans by T lymphocytes from human immunodeficiency virus-infected persons
68. Ex vivo expansion of CD4 lymphocytes from human immunodeficiency virus type 1-infected persons in the presence of combination antiretroviral agents
69. A new antisense tRNA construct for the genetic treatment of human immunodeficiency virus type 1 infection
70. Anti-HIV genetic treatment of antigen-specific human CD4 lymphocytes for adoptive immunotherapy of opportunistic infections in AIDS
71. Rational reconstitution of the immune repertoire in AIDS with autologous, antigen-specific, in vitro-expanded CD4 lymphocytes
72. Consequences of stable transduction and antigen-inducible expression of the human interleukin-7 gene on tetanus-toxoid-specific T cells
73. + cells transfected with IL-16 cDNA are resistant to HIV-1 infection: Inhibition of mRNA expression
74. Phenotypic knockout of HIV type 1 chemokine coreceptor CCR-5 by intrakines as potential therapeutic approach for HIV-1 infection
75. Interleukin-2 induced immune effects in human immunodeficiency virus-infected patients receiving intermittent interleukin-2 immunotherapy
76. + hematopoietic stem cells of HIV-infected individuals
77. + cells by transdominant negative Rev-expressing retrovirus yields partial anti-HIV protection of progeny macrophages
78. Genetic engineering of dendritic cells
79. Safety of autologous, ex vivo-expanded human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte infusion in HIV-infected patients
80. Rapid death of adoptively transferred T cells in acquired immunodeficiency syndrome
81. Transfer of HIV-1 specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression
82. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients
83. Escape of human immunodeficiency virus from immune control
84. +) T cell expansions: Evidence for impaired CTL effector function
85. + T lymphocytes armed with universal T-cell receptors
86. Lysis of HIV-1 infected cells and inhibition of viral replication by universal receptor T cells
87. Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides
88. Cytoplasmic domains of the interleukin-2 receptor beta and gamma chains mediate the signal for T-cell proliferation
89. Structure of peptides associated with class I and class II MHC molecules
90. Improved methods of HIV vector mediated gene transfer
91. Combined intra- and extracellular immunization against human immunodeficiency virus type 1 infection with a human anti-gp120 antibody
92. Intracellular antibodies (intrabodies) for gene therapy of infectious diseases
93. + T cells from HIV-infected individuals that express intracellular antibodies against HIV-1 gp120 or Tat
94. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine
95. + T cells can discriminate the molecular and structural context of T epitopes of HIV gp120 and HIV p66
96. + T cells specific for HIV gp120 and p66 (primary antigens) or for PPD and tetanus toxoid (secondary antigens)
97. + T-cell lines from HTLV-1 seronegative individuals: Specificity and clonal heterogeneity
98. T-cell repertoire diversity and clonal expansions in normal and clinical samples
99. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor
100. + T lymphocytes in patients with acquired immunodeficiency syndrome (AIDS)-related complex or AIDS
101. Directly measured kinetics of circulating T lymphocytes in normal and in HIV-1 infected humans
102. + T cell frequencies by flow-cytometry: Evidence for a novel, antigen-specific homeostatic mechanism in HIV-associated immunodeficiency
103. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA